---
document_datetime: 2025-04-03 17:28:34
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/paxneury-epar-all-authorised-presentations_en.pdf
document_name: paxneury-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 1.0803585
conversion_datetime: 2025-12-22 10:53:12.017738
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administration Immediate Packaging Pack size

| EU/1/24/1908/001   | Paxneury   | 1 mg   | Prolonged-release tablet   | Oral use   | blister (PVC/PE/PVDC/alu)   | 28 tablets   |
|--------------------|------------|--------|----------------------------|------------|-----------------------------|--------------|
| EU/1/24/1908/002   | Paxneury   | 2 mg   | Prolonged-release tablet   | Oral use   | blister (PVC/PE/PVDC/alu)   | 28 tablets   |
| EU/1/24/1908/003   | Paxneury   | 3 mg   | Prolonged-release tablet   | Oral use   | blister (PVC/PE/PVDC/alu)   | 28 tablets   |
| EU/1/24/1908/004   | Paxneury   | 4 mg   | Prolonged-release tablet   | Oral use   | blister (PVC/PE/PVDC/alu)   | 28 tablets   |
| EU/1/24/1908/005   | Paxneury   | 5 mg   | Prolonged-release tablet   | Oral use   | blister (PVC/PE/PVDC/alu)   | 28 tablets   |
| EU/1/24/1908/006   | Paxneury   | 6 mg   | Prolonged-release tablet   | Oral use   | blister (PVC/PE/PVDC/alu)   | 28 tablets   |
| EU/1/24/1908/007   | Paxneury   | 7 mg   | Prolonged-release tablet   | Oral use   | blister (PVC/PE/PVDC/alu)   | 28 tablets   |